Statement of Changes in Beneficial Ownership (4)

FORM 4

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL

OMB Number:

3235-0287

Estimated average burden
hours per response...

0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * Yankton Kevin Bruce	2. Issuer Name and Ticker or Trading Symbol Twist Bioscience Corp [ TWST ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner __X__ Officer (give title below)    _____ Other (specify below) Chief Accounting Officer
(Last)          (First)          (Middle) C/O TWIST BIOSCIENCE CORPORATION, 681 GATEWAY BLVD.	3. Date of Earliest Transaction (MM/DD/YYYY) 11/16/2021
(Street) SOUTH SAN FRANCISCO, CA 94080 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/16/2021		A		1600 (1)	A	$0	3201	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (right to buy)	$115.99	11/16/2021		A		2551		(2)	11/15/2031	Common Stock	2551	$0	2551	D

Explanation of Responses:
(1)	Represents a restricted stock unit award ("RSU") of which 25% of the total number of RSUs vest on the first anniversary of May 17, 2021 and 1/16th of the total number of RSUs vest on each quarterly anniversary thereafter, for a total vesting period of 48 months, subject to the Reporting Person's continuous service through each vesting date.
(2)	25% of the shares subject to the option vest and become exercisable on the one (1) year anniversary of May 17, 2021 and 1/48 of the shares subject to the option vest and become exercisable monthly thereafter, subject to the Reporting Person's continuous service through each vesting date.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Yankton Kevin Bruce C/O TWIST BIOSCIENCE CORPORATION 681 GATEWAY BLVD. SOUTH SAN FRANCISCO, CA 94080			Chief Accounting Officer

Signatures
/s/ William Solis, Attorney-in-Fact for Kevin B. Yankton		11/30/2021
**Signature of Reporting Person		Date